Author:
Pawar Samadhan P.,Walekar Laxman S.,Kondekar Uttam R.,Gunjal Dattatray B.,Gore Anil H.,Anbhule Prashant V.,Patil Shivajirao R.,Kolekar Govind B.
Subject
Analytical Chemistry,Electrochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Pharmacy
Reference41 articles.
1. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors;Miller;Drug Dev. Res.,1993
2. Dolasetron mesylate;Galvan;Drugs Futur.,1993
3. Guidance for Industry E14 Clinical Evaluation of QT/QTcInterval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, U. S. Food and Drug Administration, 2005, Available at: 〈http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm〉
4. Basic and Clinical Pharmacology;Katzung,2004
5. Determination of dolasetron and its reduced metabolite in human plasma by GC–MS and LC;Gillespie;J. Pharm. Biomed. Anal.,1993
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献